Pfizer (BOM:500680) Cyclically Adjusted Revenue per Share: ₹613.62 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500680 Pfizer Ltd BOM:500680
69 GF Score
Price ₹4,800.80
GF Value ₹5,222.05
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pfizer Cyclically Adjusted Revenue per Share?

Pfizer BOM:500680 -0.57% 69 Cyclically Adjusted Revenue per Share is ₹613.62 as of Jun. 2026. GuruFocus rates BOM:500680 with a GF Score™ of 69/100 and a GF Value™ of ₹5,222.05 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pfizer's adjusted revenue per share for the three months ended in Jun. 2026 was ₹142.760. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹613.62 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Pfizer's average Cyclically Adjusted Revenue Growth Rate was 1.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 0.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pfizer was 5.20% per year. The lowest was 0.70% per year. And the median was 3.20% per year.

As of today (2026-08-19), Pfizer's current stock price is ₹4800.80. Pfizer's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹613.62. Pfizer's Cyclically Adjusted PS Ratio of today is 7.82.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pfizer was 11.12. The lowest was 5.81. And the median was 7.90.


Pfizer  (BOM:500680) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pfizer's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4800.80/613.62
=7.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pfizer was 11.12. The lowest was 5.81. And the median was 7.90.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pfizer Cyclically Adjusted Revenue per Share Related Terms


Pfizer Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Pfizer's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Cyclically Adjusted Revenue per Share Chart

Pfizer Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 567.09 596.31 613.14 598.47 609.26

Pfizer Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 603.57 608.67 609.20 609.26 613.62

BOM:500680 vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pfizer's Cyclically Adjusted PS Ratio falls into.


BOM:500680
69GF Score
Pfizer Ltd BOM:500680
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pfizer's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=142.76/167.3573*167.3573
=142.760

Current CPI (Jun. 2026) = 167.3573.

Pfizer Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 117.058 105.961 184.884
201612 107.410 105.196 170.880
201703 95.736 105.196 152.307
201706 92.030 107.109 143.797
201709 124.806 109.021 191.588
201712 99.797 109.404 152.661
201803 113.633 109.786 173.221
201806 111.956 111.317 168.319
201809 113.604 115.142 165.122
201812 112.306 115.142 163.235
201903 117.079 118.202 165.767
201906 119.005 120.880 164.762
201909 123.964 123.175 168.429
201912 117.653 126.235 155.979
202003 109.694 124.705 147.212
202006 112.534 127.000 148.294
202009 130.122 130.118 167.363
202012 129.716 130.889 165.857
202103 116.854 131.771 148.412
202106 163.732 134.084 204.362
202109 139.091 135.847 171.354
202112 147.757 138.161 178.982
202203 120.126 138.822 144.818
202206 129.508 142.347 152.262
202209 139.332 144.661 161.192
202212 135.896 145.763 156.029
202303 124.628 146.865 142.018
202306 116.124 150.280 129.320
202309 125.732 151.492 138.900
202312 118.065 152.924 129.208
202403 119.374 153.035 130.546
202406 123.021 155.789 132.156
202409 128.645 157.882 136.365
202412 117.591 158.323 124.301
202503 129.385 157.552 137.438
202506 131.806 159.755 138.078
202509 140.418 162.289 144.803
202512 141.021 163.281 144.542
202603 137.549 164.272 140.132
202606 142.760 167.357 142.760

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹613.62 mean?
Pfizer (BOM:500680) has a Cyclically Adjusted Revenue per Share of ₹613.62 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pfizer and its competitors.
Is Pfizer's Cyclically Adjusted Revenue per Share too high?
Pfizer's current Cyclically Adjusted Revenue per Share is ₹613.62. Overall, Pfizer has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Pfizer's Cyclically Adjusted Revenue per Share of ₹613.62 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pfizer and its competitors. Pfizer's current Cyclically Adjusted Revenue per Share is ₹613.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (BOM:500680) is currently considered Fairly Valued. The stock's GF Value™ is ₹5,222.05, compared to a current price of ₹4,800.80 — trading 8.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹613.62. Pfizer's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Pfizer (BOM:500680), the current Cyclically Adjusted Revenue per Share is ₹613.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (BOM:500680) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of ₹4,800.80 is trading 8.1% below its estimated GF Value™ of ₹5,222.05. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for BOM:500680:

  • Cyclically Adjusted Revenue per Share: ₹613.62
  • GF Value™: ₹5,222.05 vs. price of ₹4,800.80 (8.1% below fair value)
  • GF Score™: 69/100 with 1 warning sign

No single metric tells the full story. See the BOM:500680 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pfizer Business Description

Other Exchanges PFIZER:India
Address The Capital, 1802/1901, 18th Floor, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The company has only one segment which is Pharmaceuticals and it operates in domestic market.
69GF Score

Get the complete analysis for BOM:500680

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹4,800.80
Price
₹5,222.05
GF Value